The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type
Background: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic,...
Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab
Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts...
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab
Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in...
Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab
Background: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of...
US Real World Experience Switching from Infusion and S1P Therapies to Cladribine Tablets: A Single Center Study
Background: Multiple sclerosis (MS) is a chronic neurological disorder and a major cause of disability in young adults. Cladribine tablets...
Early Experience with Cladribine Tablets in an Aging Patient Population
Background: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade...
Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab
Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an...
Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)
Background: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more...
B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study
Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS...
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment
Background: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing...